Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | Genetic mechanisms driving thrombocytopenia in MF patients

In this video, Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, shares some insights into a study which investigated genetic mechanisms driving thrombocytopenia in patients with myelofibrosis (MF). Dr Kuykendall first explains the methodology used in this study, and then goes on to discuss some results, which suggested that disease-related thrombocytopenia was associated with three unique prognostic factors: presence of a TP53 mutation, presence of an SRSF2 mutation, and low serum albumin. To conclude, Dr Kuykendall comments on how the identification of these genetic factors may be used to improve prognosis and patient outcome. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research fees – Morphosys, GSK
Honoraria – Incyte